Key Points
- CEO Ivor Elrifi purchased 237,616 Tiziana Life Sciences shares at an average price of $1.00, increasing his direct ownership by 5.22% to 4.79 million shares. He also bought 750,807 shares in two transactions earlier that week.
- Tiziana shares opened at $0.97, down 1.6%, and remain near the lower end of their 52-week range of $0.87 to $2.53. The stock’s 50-day and 200-day moving averages were $1.14 and $1.30, respectively.
- Analyst sentiment remains cautious, with ratings split between Hold and Sell and a consensus rating of “Reduce,” despite some hedge funds recently increasing or initiating positions.
Tiziana Life Sciences Ltd (NASDAQ:TLSA - Get Free Report) CEO Ivor Elrifi bought 83,807 shares of the stock in a transaction on Tuesday, August 4th. The shares were bought at an average cost of $0.97 per share, with a total value of $81,292.79. Following the purchase, the chief executive officer owned 4,556,068 shares of the company's stock, valued at $4,419,385.96. This trade represents a 1.87% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Ivor Elrifi also recently made the following trade(s):
- On Wednesday, August 5th, Ivor Elrifi bought 237,616 shares of Tiziana Life Sciences stock. The stock was purchased at an average cost of $1.00 per share, with a total value of $237,616.00.
- On Monday, August 3rd, Ivor Elrifi acquired 667,000 shares of Tiziana Life Sciences stock. The stock was acquired at an average price of $1.00 per share, with a total value of $667,000.00.
Tiziana Life Sciences Stock Performance
NASDAQ:TLSA opened at $0.97 on Friday. Tiziana Life Sciences Ltd has a 52 week low of $0.87 and a 52 week high of $2.53. The company has a fifty day simple moving average of $1.14 and a two-hundred day simple moving average of $1.30.
Analyst Ratings Changes
TLSA has been the topic of several recent analyst reports. Weiss Ratings lowered Tiziana Life Sciences from a "sell (d-)" rating to a "sell (e+)" rating in a report on Friday, May 29th. Wall Street Zen cut shares of Tiziana Life Sciences from a "hold" rating to a "sell" rating in a research note on Saturday, April 18th. Finally, Zacks Research raised Tiziana Life Sciences to a "hold" rating in a report on Tuesday, July 14th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Reduce".
View Our Latest Analysis on Tiziana Life Sciences
Institutional Investors Weigh In On Tiziana Life Sciences
Several hedge funds have recently modified their holdings of TLSA. Millennium Management LLC purchased a new stake in shares of Tiziana Life Sciences in the third quarter valued at $520,000. Jane Street Group LLC increased its position in shares of Tiziana Life Sciences by 968.2% in the first quarter. Jane Street Group LLC now owns 167,542 shares of the company's stock worth $181,000 after acquiring an additional 151,858 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in Tiziana Life Sciences by 413.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 110,290 shares of the company's stock valued at $164,000 after purchasing an additional 88,830 shares in the last quarter. Bison Wealth LLC acquired a new stake in shares of Tiziana Life Sciences in the fourth quarter valued at about $30,000. Finally, OMERS ADMINISTRATION Corp acquired a new stake in Tiziana Life Sciences in the fourth quarter valued at approximately $59,000.
Tiziana Life Sciences Company Profile
(
Get Free Report)
Tiziana Life Sciences plc (NASDAQ: TLSA) is a clinical-stage biotechnology company focused on the development of novel therapeutics in the fields of oncology, immunology and infectious diseases. Headquartered in London, with research and development operations in Cambridge, Massachusetts, the company advances both small-molecule inhibitors and monoclonal antibody candidates designed to modulate immune pathways and target tumor growth.
The company's lead small‐molecule program, milciclib, is an oral cyclin‐dependent kinase inhibitor currently in Phase II clinical trials for hepatocellular carcinoma and certain neuroendocrine tumors.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
